Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$37.1 million.

  • Spyre Therapeutics' Free Cash Flow fell 2615.82% to -$37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$161.9 million, marking a year-over-year decrease of 702.56%. This contributed to the annual value of -$157.4 million for FY2024, which is 5755.18% down from last year.
  • Spyre Therapeutics' Free Cash Flow amounted to -$37.1 million in Q3 2025, which was down 2615.82% from -$46.6 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Free Cash Flow ranged from a high of $2.1 million in Q2 2021 and a low of -$62.2 million during Q2 2024
  • Its 5-year average for Free Cash Flow is -$27.1 million, with a median of -$26.3 million in 2022.
  • Per our database at Business Quant, Spyre Therapeutics' Free Cash Flow skyrocketed by 10989.49% in 2021 and then plummeted by 110745.61% in 2022.
  • Over the past 5 years, Spyre Therapeutics' Free Cash Flow (Quarter) stood at -$19.3 million in 2021, then grew by 5.85% to -$18.1 million in 2022, then crashed by 71.09% to -$31.0 million in 2023, then fell by 19.86% to -$37.2 million in 2024, then grew by 0.22% to -$37.1 million in 2025.
  • Its Free Cash Flow stands at -$37.1 million for Q3 2025, versus -$46.6 million for Q2 2025 and -$41.0 million for Q1 2025.